HomeComparePZRXQ vs KMB

PZRXQ vs KMB: Dividend Comparison 2026

PZRXQ yields 2000000.00% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PZRXQ wins by $4.879226400974806e+39M in total portfolio value
10 years
PZRXQ
PZRXQ
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full PZRXQ calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — PZRXQ vs KMB

📍 PZRXQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPZRXQKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PZRXQ + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PZRXQ pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PZRXQ
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, PZRXQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PZRXQ + KMB for your $10,000?

PZRXQ: 50%KMB: 50%
100% KMB50/50100% PZRXQ
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

PZRXQ
No analyst data
Altman Z
-25.0
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PZRXQ buys
0
KMB buys
6
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$KMB▼ Sell$1,001 - $15,0002025-11-12
Ro Khanna🏢 House$KMB▼ Sell$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$KMB▼ Sell$1,001 - $15,0002025-09-05
Lisa McClain🏢 House$KMB▼ Sell$1,001 - $15,0002025-07-16
Lisa McClain🏢 House$KMB▲ Buy$1,001 - $15,0002025-07-10
Rob Bresnahan🏢 House$KMB▼ Sell$1,001 - $15,0002025-05-15
Rob Bresnahan🏢 House$KMB▼ Sell$1,001 - $15,0002025-04-08
Julie Johnson🏢 House$KMB▼ Sell$1,001 - $15,0002025-04-01
Ro Khanna🏢 House$KMB▲ Buy$1,001 - $15,0002024-11-15
Tommy Tuberville🏛 Senate$KMB▼ Sell$15,001 - $50,0002024-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPZRXQKMB
Forward yield2000000.00%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$4.879226400974806e+39M$45.9K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$5,211.33
Total dividends collected$4.879195005460081e+39M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PZRXQ vs KMB ($10,000, DRIP)

YearPZRXQ PortfolioPZRXQ Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,314$613.68+$200.00MPZRXQ
2$3,738,731,768,458$3,738,517,757,009.35$12,865$759.19+$3738731.76MPZRXQ
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,709$943.96+$65315062866.92MPZRXQ
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$16,919$1,180.17+$1066400830062625.00MPZRXQ
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$19,588$1,484.33+$16272182796453826560.00MPZRXQ
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$22,838$1,879.06+$2.3205424011366188e+23MPZRXQ
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$26,832$2,395.60+$3.0927990661046884e+27MPZRXQ
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$31,788$3,077.63+$3.8524105697352695e+31MPZRXQ
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$38,000$3,986.82+$4.484688260147987e+35MPZRXQ
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$45,872$5,211.33+$4.879226400974806e+39MPZRXQ

PZRXQ vs KMB: Complete Analysis 2026

PZRXQStock

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Full PZRXQ Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this PZRXQ vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PZRXQ vs SCHDPZRXQ vs JEPIPZRXQ vs OPZRXQ vs KOPZRXQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.